Baricitinib NEW

Manufacturer Provide Pharmaceutical Intermediate Raw Material Baricitinib Powder CAS 1187594-09-7 Baricitinib

Introduction

Product Name: Baricitinib

Other Name :1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile;Baricitinib

CAS NO:1187594-09-7

Purity: 99%min
Appearance:White crystalline powder

Molecular formula:C16H17N7O2S

MW:371.42

Melting Pint :212-215°C

Density :1.56

Storage :Keep in dark place,Inert atmosphere,Room temperature

Baricitinib (baricitinib) obtained FDA emergency authorization (EUA) to be used in combination with Redecivir to improve patients who require supplemental oxygen, intubation ventilation or extracorporeal membrane oxygenation, children over 2 years of age, or adult hospitalized patients with new coronary pneumonia or Suspected patient. The FDA emergency authorization is based on a clinical trial (ACTT-2) conducted by the National Institute of Allergy and Infectious Diseases (ACTT-2). Compared with radcivir monotherapy, baritinib is combined with radcivir. It can reduce the patient's recovery time during the 29-day improvement period.